Royalty revenue increased by 3% to $66.9 million for the three months to June 30, 2009 (2008: $64.8 million). The following table provides an analysis of Shire's royalty income:
Product Royalties to Shire $M Year on year change(1) 3TC 29.2 -18% ZEFFIX 10.2 -6% ADDERALL XR 13.6 n/a Other 13.9 -25% Total 66.9 3% (1) Compared with Q2 2008 3TC - HIV infection and AIDS
Shire receives royalties from GSK on worldwide sales of 3TC(R) sales. Royalties from sales of 3TC for the three months to June 30, 2009 were $29.2 million (2008: $35.6 million). Excluding unfavorable foreign exchange movements of 7%, royalties have decreased by 11% mainly due to competition from other HIV treatments.
ZEFFIX - Chronic hepatitis B infection
Shire receives royalties from GSK on worldwide ZEFFIX(R) sales. Royalties from sales of ZEFFIX for the three months to June 30, 2009 were $10.2 million, a decrease of 6% (2008: $10.8 million). The impact of foreign exchange movements has contributed 4% to the reported decrease, with the remainder of the decrease due to increased competition from other hepatitis B treatments.
ADDERALL XR - ADHD
Royalties from Teva's sales of authorized generic ADDERALL XR for the
three months to June 30, 2009 were $13.6 m
|SOURCE Shire Plc|
Copyright©2009 PR Newswire.
All rights reserved